InMed Pharmaceuticals (INM) Net Income towards Common Stockholders (2021 - 2026)

InMed Pharmaceuticals' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$174585.0 for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 224.14% year-over-year to -$174585.0; the TTM figure through Mar 2026 stood at -$5.2 million (up 16.05% YoY), while the FY2025 annual figure was -$8.2 million, down 6.34% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$174585.0, up from -$2.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$53861.0 in Q1 2025, with the low at -$7.9 million in Q2 2022.
• The 5-year median for Net Income towards Common Stockholders is -$1.9 million (2024), against an average of -$2.1 million.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders slumped 473.57% in 2024, then jumped 96.87% in 2025.
• InMed Pharmaceuticals' Net Income towards Common Stockholders stood at -$2.1 million in 2022, then advanced by 29.55% to -$1.5 million in 2023, then slumped by 74.2% to -$2.6 million in 2024, then advanced by 21.23% to -$2.0 million in 2025, then soared by 91.39% to -$174585.0 in 2026.
• Business Quant data shows INM's Net Income towards Common Stockholders at -$174585.0 in Q1 2026, -$2.0 million in Q4 2025, and -$1.7 million in Q3 2025.